Open AccessAbscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
Author(s) -
Zhuang Hongqing
Publication year - 2020
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12111
Subject(s) - sabr volatility model , abscopal effect , medicine , radiation therapy , immunotherapy , oncology , lung cancer , radiosurgery , cancer immunotherapy , cancer , cancer research , volatility (finance) , stochastic volatility , financial economics , economics
Immunotherapy, as one of the major strategies for cancer treatment, has shown promising efficacy in cancer treatment by the clinical application of programmed cell death protein-1/ programmed cell death-ligand 1 (PD-1/PD-L1) antibodies which have demonstrated a significant prolongation in the survival time of melanoma, lung, and liver cancer patients. [1–3]. Meanwhile, the clinical observation of partial responses in unirradiated lesions after radiotherapy, termed as abscopal effect, has gradually attracted a lot of attention and has inspired oncologists to combine stereotactic radiotherapy (SABR) with immunotherapy for improving clinical outcomes. It is the abscopal effect phenomenon that crucially determines the anti-tumor efficiency of SABR and immune checkpoint inhibitors combination strategy [4]. However, due to the short application time and limited experience of the clinical utilization of SABR and anti-PD-1/PD-L1 combination therapy, there are plenty of theoretical and practical issues that need to be systematically discussed, including the mechanisms underlying an abscopal effect, the efficacy and toxicity of combination therapy, and the validity or reliability of corresponding clinical trials. Here, we reviewed previous landmark reports and summarized the research progress of SABR combined with anti-PD-1/PLD1 therapy to improve the understanding on abscopal effect.